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Abstract
Background: Autosomal dominantly inherited PRKAG2 cardiac syndrome is due to a unique defect of the cardiac
cell metabolism and has a distinctive histopathology with excess intracellular glycogen, and prognosis different
from sarcomeric hypertrophic cardiomyopathy. We aimed to define the distinct characteristics of PRKAG2 using
cardiovascular magnetic resonance (CMR).
Methods: CMR (1.5 T) and genetic testing were performed in two families harboring PRKAG2 mutations. On CMR,
segmental analysis of left ventricular (LV) hypertrophy (LVH), function, native T1 mapping, and late gadolinium
enhancement (LGE) were performed.
Results: Six individuals (median age 23 years, range 16–48; two females) had a PRKAG2 mutation: five with an
R302Q mutation (family 1), and one with a novel H344P mutation (family 2). Three of six mutation carriers had LV
mass above age and gender limits (203 g/m2, 157 g/m2 and 68 g/m2) and others (with R302Q mutation) normal
LV masses. All mutation carriers had LVH in at least one segment, with the median maximal wall thickness of
13 mm (range 11–37 mm). Two R302Q mutation carriers with markedly increased LV mass (203 g/m2 and 157 g/m2)
showed a diffuse pattern of hypertrophy but predominantly in the interventricular septum, while other mutation
carriers exhibited a non-symmetric mid-infero-lateral pattern of hypertrophy. In family 1, the mutation negative male
had a mean T1 value of 963 ms, three males with the R302Q mutation, LVH and no LGE a mean value of 918 ± 11 ms,
and the oldest male with the R302Q mutation, extensive hypertrophy and LGE a mean value of 973 ms. Of six
mutations carriers, two with advanced disease had LGE with 11 and 22 % enhancement of total LV volume.
Conclusions: PRKAG2 cardiac syndrome may present with eccentric distribution of LVH, involving focal
mid-infero-lateral pattern in the early disease stage, and more diffuse pattern but focusing on interventricular septum
in advanced cases. In patients at earlier stages of disease, without LGE, T1 values may be reduced, while in the
advanced disease stage T1 mapping may result in higher values caused by fibrosis. CMR is a valuable tool in detecting
diffuse and focal myocardial abnormalities in PRKAG2 cardiomyopathy.
Background
PRKAG2 cardiac syndrome is an autosomal dominantly
inherited metabolic heart muscle disease characterized
by left ventricular hypertrophy (LVH), progressive con-
ducting abnormalities and ventricular pre-excitation
(Wolff-Parkinson-White [WPW] syndrome) [1–4]. The
prevalence is approximately 0.23–1 % in patients with
hypertrophic cardiomyopathy (HCM) [4, 5]. Despite of
the rarity, PRKAG2 accounts for a greater proportion of
HCM in children and adolescents [6], and patients may
benefit from early identification due to high risk of
complete atrioventricular block [4, 7] and sudden cardiac
death caused by atrial fibrillation and rapid antegrade con-
duction through an accessory pathway [8].
Patients with a PRKAG2 gene defect have a distinctive
cardiac histopathology with excess intracellular vacuoles
filled with glycogen, myocyte enlargement but without
myocyte disarray typical for sarcomeric HCM [3]. How-
ever, there are relatively few histopathological reports on
PRKAG2 syndrome hearts, and in some cases abundant
interstitial fibrosis and myocyte disarray in the absence of
glycogen accumulation has been reported [4, 9]. Recently,
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severe fibrofatty myocardial replacement has been de-
scribed in a patient with end-stage PRKAG2 [10].
In HCM, standard cardiovascular magnetic resonance
(CMR) with late gadolinium enhancement (LGE) tech-
nique enables accurate assessment of myocardial morph-
ology and function. While LGE visualizes the expansion
of extracellular space related to focal myocardial fibrosis
or infiltration [11, 12], T1 mapping has become a prom-
ising tool for evaluation of diffuse myocardial disease.
Native T1 mapping reflects both intra- and extracellular
signal in the myocardium [13]. Elevated native T1 times
have been reported in fibrosis [14], edema [15] and
amyloidosis [16], and lowered in iron overload [17] and
focal fat infiltration [18]. Recently, native T1 mapping
showed potential in the identification of Anderson-Fabry
disease, a genetic storage disease characterized by multior-
gan involvement and sphingolipid accumulation within
myocytes [18, 19]. Metabolic defect resulting in macro-
molecular intracellular glycogen, and even lipid accumula-
tion, may reduce native T1-relaxation time [20, 21], in the
absence of significant extracellular fibrosis which is often
seen in other forms of HCM.
To our knowledge, two case reports of CMR findings in
PRKAG2 cardiomyopathy have been reported [22, 23]. As
PRKAG2 cardiac syndrome is a unique glycogen storage
cardiomyopathy, we sought whether CMR might demon-
strate different imaging characteristics from sarcomeric
HCM or hypertensive heart disease.
Methods
Patient population
This study was performed at the Helsinki University
Central Hospital. All participants gave written informed
consent and the project was approved by the local institu-
tional ethics committee. Seven subjects from two separate
families harboring PRKAG2 mutations were recruited
to this study. Two of the patients had a pacemaker
system [24].
Clinical evaluation of all study subjects comprised re-
view of hospital records, 12-lead electrocardiography
(ECG) and echocardiography (index patients). Patients
underwent electrophysiological study based on the treat-
ing cardiologist’s decision.
The phenotypic triad of PRKAG2 cardiac syndrome was
based on observed cardiac hypertrophy, pre-excitation
and conduction system disease [25]. Ventricular pre-
excitation was defined as a short PR interval (<120 ms),
widened QRS interval (>110 ms), and an abnormal initial
QRS vector (delta-wave), or demonstration of an antegra-
dely conducting accessory pathway on electrophysiologic
study. Evidence of supraventricular tachycardia in associ-
ation with pre-excitation defined WPW [25]. Diagnosis of
conduction system disease required sinus node dysfunc-
tion or atrioventricular block on ECG.
Genetic analysis
A novel next generation sequencing (NGS) strategy,
oligonucleotide-selective sequencing [26], targeting 69
known genes associated with cardiomyopathies (Core Car-
diomyopathy Panel, Blueprint Genetics, Helsinki, Finland,
http://blueprintgenetics.com/), was used to examine the
index patient in family 1. Median sequence coverage per
base pair was 137x and 97.3 % of the target region was
covered with >15x. Sequence analysis identified a hetero-
zygous missense variant in the PRKAG2 gene, c.905G >A
(p.R302Q), which has been well characterized by several
scientific reports as a disease mutation associated with
dominantly inherited WPW and severe LVH resembling
clinically HCM [2, 7, 9]. Direct Sanger sequencing was
used to confirm the detected variant and family member
testing.
The index patient in family 2 was screened using a
custom-designed panel of 117 cardiomyopathy-related
genes (HaloPlex kit of 500Kb, Agilent Technologies) and
a heterozygous missense mutation was identified in the
PRKAG2 gene. The novel mutation p.H344P (c.1031A > C)
was shown to segregate with the disease in the family and
was absent in 3250 Finnish controls (Sequencing Initiative
Suomi (SISu) database, http://www.sisuproject.fi/). The
p.H344P mutation alters an evolutionarily conserved site
in the protein, indicating that this amino acid presents an
important role for the structure and the function of the
protein. The variant was rated as deleterious and possibly
damaging by the bioinformatics prediction tools SIFT and
PolyPhen-2 respectively, strengthening the idea that this is
a pathogenic variant.
CMR technique
CMR was performed with 1.5 T MR scanner (Avantofit;
Siemens, Erlangen, Germany) using a 32-channel receiver
cardiac coil. Breath-hold cine MR was performed using
retrospectively electrocardiographically gated segmented
true fast imaging with balanced steady-state free precession
(bSSFP) TrueFISP sequence. To assess left (LV) and right
(RV) ventricular volumes and ejection fractions (EF) cine
MR images were obtained in vertical, and horizontal long-
axis, and a stack of short-axis planes covering both ventri-
cles. Three-chamber view was obtained to assess LV out-
flow tract. The typical imaging parameters were TR/TE
3.0/1.6 ms, flip angle 52°, 256 × 256 matrix, 240 × 340 mm
field of view (FOV). Slice thickness was 6 mm and inter-
slice gap 20 %. The temporal resolution was 42–49 ms.
Myocardial T1 mapping was performed in a mid-
ventricular short-axis slice using a shortened Modified
Look-Locker Inversion-recovery (ShMOLLI) sequence.
Typical acquisition parameters for ShMOLLI sequence
were TR/TE 2.1/1.1 ms, flip angle 35°, 236 × 256 matrix
and 331 × 360 mm FOV, inversion times varying from
90 ms to circa 5000 ms, and 8 mm slice thickness.
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Quantitative myocardial T2 mapping was performed in
a breath-hold fashion by using a T2-prepared bSSFP se-
quence to produce three single-shot T2-weighted images,
each with different T2-preparation times (TET2P = 0 ms,
25 ms and 55 ms). The other scanning parameters were as
follows: TR = 4 × RR intervals, flip angle 35°, 192 × 154
matrix, 360 × 289 mm FOV, and 8 mm slice thickness.
Ten minutes after injection of a contrast agent (gadoter-
atemeglumine, Dotarem® 0.2 mmol/kg) LGE images were
acquired in the same views as for cine images, using inver-
sion recovery spoiled gradient echo (IR-SPGR) sequence.
The imaging parameters were TR/TE 2.58/2.3 ms, flip
angle 50°, 256 × 256 matrix, 240 × 340 FOV. Slice thick-
ness was 8 mm and interslice gap 0 %. Inversion time was
optimized for each measurement to null the signal inten-
sity of normal myocardium (240–360 ms).
Imaging of two patients with a permanent pacemaker
device were performed according to previously published
MR safety protocol for the pacemaker patients [24].
Image analysis
Images were analyzed in consensus with two experi-
enced (>10 years of experience) cardiac radiologists (SK,
MH). In each patient, the three LV short axis sections
were divided into 17 segments according to American
Heart Association (AHA) guidelines [27]. Segments with
any artifacts due to a pacemaker were excluded in all
analysis.
Volumes, mass and wall thickness were assessed using
standard protocols [28]. Imaging analysis was performed
using QMass MR software® (version 7.6, Medis Medical
Imaging Systems, Leiden, Netherlands). Cardiac hyper-
trophy was defined as increased LV wall thickness in one
or more myocardial segments, or RV free wall thickness,
of more than two standard deviations above the popula-
tion mean (z-score > 2) on CMR.
Motion corrected T1 maps were generated and T1 esti-
mates were computed on a per-pixel basis by performing
a non-linear curve fitting using the three parameter signal
model. We performed “midwall myocardial” segmental T1
analysis by measuring the mean T1-relaxation values sep-
arately for the anterior, anteroseptal, inferoseptal, inferior,
inferolateral and anterolateral segments of myocardium
(six segments). In addition to segmental analysis we also
calculated the mean T1 value of the mid-myocardium. T1
values were compared with published values for normal
healthy myocardium [29].
Acquired T2 images were motion corrected to in-
plane motion between images by using a fast non-rigid
registration algorithm. A pixel-wise myocardial T2 maps
were generated using curve-fitting based on two parameter
equation by assuming mono-exponential signal decay. Seg-
mental analysis was performed for myocardial T2 values
similarly as for T1 values.
The LGE percentage of LV was calculated using QMass
MR software®. Hyperenhanced pixels were defined using
full width at half maximum method.
Statistical analysis
Continuous variables are presented as median (range) or
mean ± standard deviation (SD) as appropriate, and
categorical variables as frequency (%), unless otherwise
mentioned. Comparison between continuous normally
distributed variables was performed with Student’s t-test.
Results are given as absolute values and standardized
to age, gender, body surface area (BSA, Mosteller’s
method) and normal myocardial function (z-scores).
Normal ventricular volumes and masses for adults were
obtained from the references [28, 30] and for children
(<18 years) from the reference [31], using similar 1.5 T
MR scanner and bSSFP pulse sequence as ours.
Mean and maximal wall thickness of each of the 16 LV
segments (apex left out) are presented as absolute (mm)
and standardized (z-scores) values, with the aim to esti-
mate the real distribution of segmental hypertrophy in
relation to normal changes in wall thickness through the
myocardium. Normal LV wall thickness values for adults
were obtained from the reference [32] (similar scanner,
sequence and QMass software tool as ours). Maximal
absolute and standardized wall thickness values do not
always represent the same segment.
Currently, there are no available reference values for
LV wall thickness based on the 17-segment-model for
children. Therefore, we used adult CMR references for
the 17-year-old female (BSA 1.83 m2) and for the 16-year-
old male (BSA 1.33 m2). BSA-standardized echocardio-
graphic reference values were also used for all children for
measurement of maximal wall thickness [33].
To take into account clustering and correlation of data
within patients and myocardial segments, the association
between segmental T1 values and hypertrophy were ana-
lysed using a linear mixed effects model, with patients
treated as a random intercept and segments having a
fixed effect on T1.
A p-value of < 0.05 was considered statistically signifi-
cant and all tests were 2-sided. Statistical analysis was
performed using the SPSS 21 package (SPSS, Chigaco,
IL, USA). R language and environment for statistical
computing (Version 2.15.3, R Core Team 2013, R Foun-
dation for Statistical Computing, Vienna, Austria) was
used for graphical output of segmental LV wall thickness
and linear mixed effects model analysis.
Results
Study patients
Of the seven individuals examined with CMR in two
separate families (Fig. 1a and b), altogether six had a
PRKAG2 mutation: five R302Q mutations in family 1
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and one novel H344P mutation in family 2. The median
age of the six mutation carriers (two females) was 23 years
(range 16–48 years) and BSA 1.76 m2 (range 1.33–
1.88 m2). One 19-year-old male did not have a PRKAG2
mutation. Six mutation carriers completed otherwise full
CMR imaging protocol, but one patient missed T1 and T2
mapping.
Clinical features of examined family members are pre-
sented in Table 1, and an abnormal electrocardiogram of
a patient with the R302Q mutation in Fig. 1c. Based on
hospital records, no other risk factors for LVH such as
hypertension or chronic kidney diseases were detected
in patients examined with CMR.
Ventricular volumes, function and hypertrophy
All six PRKAG2 mutation carriers had preserved age,
gender and BSA standardized LV and RV end-diastolic
volume (EDV), stroke volume and EF, see Table 2. How-
ever, three of six had LV mass above age and gender
limits. In family 1, two R302Q mutation carriers (aged 23
and 48 years) had markedly elevated LV mass (203 g/m2
[z-score 18.8] and 157 g/m2 [9.6]) (Fig. 2) and three (aged
16, 24 and 26 years) normal LV masses (Fig. 3). In family
2, the 17-year-old female with an H344P mutation had
also elevated LV mass (68 g/m2 [2.2]).
All mutation carriers had LVH by definition, i.e., wall
thickness > 2 z-scores in one or more LV myocardial
Fig. 1 Pedigrees of two families with PRKAG2 cardiac syndrome and consequent clinical phenotypes of patients. Individuals with a PRKAG2
mutation (+) were identified, with R302Q substitution in family 1 (a) and H344P substitution in family 2 (b). Squares indicate males and circles
females. Filled symbols indicate disease phenotype in affected individuals, i.e., cardiac hypertrophy (left half filled), pre-excitation (right upper
quadrant filled), or conduction system disease (right lower quadrant filled). Open symbols denote unaffected individuals and shading denotes
uncertain clinical status. Arrows indicate index patients. The electrocardiogram of a patient with the R302Q mutation (c). Atrial pacing with large
QRS deflections and pathologic T waves
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Table 1 Clinical features of study individuals
PRKAG2
mutation
Age at
CMR (yrs)
Age at
Dx (yrs)
Sex Pre-excitation WPW Conduction
system
diseasea
PM EP study ±
RF ablation
Syncope Cardiac
hypertrophy
Tx Death Blood pressure
(systolic/diastolic)
mmHg
NYHA
functional
class
Serum
Creatinine
(μmol/l)
Hemoglobin
(g/l)
NT-proBNB
(ng/l)
Family 1
I:1 R302Q 48 30 M - - + + - + + - - 136/80 1 91 165 b
II:1 R302Q 26 8 M + + - - + + + - - 113/69 1 83 153 31
II:2 R302Q 24 24 M - - - - + - + - - 110/57 1 b b 25
II:3 R302Q 23 5 F - - + + - - + - - 127/56 1 63 115 1078
II:4 None 19 M - - - - - - - - - 124/62 1 b b b
II:5 R302Q 16 16 M - - - - - - + - - 115/63 1 b b b
Family 2
I:1 H344P c 24 M - - + + - + + + + 160/100 3 58 120 39
II:1 H344P 17 10 F + + - - + - + - - 116/65 1 129 146 1330
Mutation nomenclature is based on GenBank accession NM_016203.3 (PRKAG2) with nucleotide one being the first nucleotide of the translation initiation codon ATG
Abbreviations: CMR cardiovascular magnetic resonance, Dx diagnosis, EP electrophysiologic, F female, LVH left ventricular hypertrophy, M male, NT-proBNB N-terminal of the prohormone brain natriuretic peptide, NYHA
New York Heart Association, PM permanent pacemaker, RF radiofrequency, Tx cardiac transplantation, WPW Wolff-Parkinson-White syndrome
aSinus node dysfunction or atrioventricular block on ECG
bData not available
cWas not examined with CMR. Cardiac hypertrophy diagnosis was based on the explanted heart
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segments, with the median maximal wall thickness of
13 mm (range 11–37 mm) and z-score of 3.2 (range
2.3–19.0), see Table 3. Segmental distribution of max-
imal wall thickness had two different patterns (Fig. 4).
Two symptomatic R302Q mutation carriers (aged 48
and 23 years) with markedly increased LV mass had
hypertrophy throughout the myocardium, but predomin-
antly in the interventricular septum (Fig. 4a and d), with
the maximal (based on z-scores) wall thickness of 31 mm
(z-score 11.8) and 37 mm (19.0) in the mid-anteroseptal
segment in both patients. Trabeculae or papillary muscles
were excluded in the measurements. Other mutation
carriers with normal or only mildly increased LV mass
(three R302Q carriers: aged 26, 24 and 16 years; one
H344P carrier: aged 17 years) had LV hypertrophy in a
non-symmetric pattern with the maximal wall thickness
located in mid-inferolateral or mid-inferior segments
(Fig. 4b, c, e and f).
The median RV free wall thickness was 5 mm (range
2–6 mm).
T1 and T2 mapping
In family 1, the mutation negative male (19 years old)
had a mean T1 value of 963 ms, see Table 4. Three male
siblings (26, 24 and 16 years) with the R302Q mutation,
asymmetric LVH and without LGE, had a mean T1 value
of 918 ± 11 ms. The oldest male in the family (48 years)
with the R302Q mutation, extensive hypertrophy and LGE,
had a mean T1 value of 973 ms (mid-anteroseptal, −anter-
ior and -anterolateral segments excluded due to artifact
caused by pacemaker), while corresponding segments had
a mean LGE volume of 8 %.
Considering 18 non-enhanced mid-myocardial segments
in three male R302Q carriers, there was a trend toward sig-
nificant inverse association between segmental T1 times
and hypertrophy (segments with wall thickness z-score > 2
had a mean T1 value of 909 ± 16 ms versus other segments
925 ± 17 ms; p = 0.054). However, after adjustment to fixed
effects caused by different segments on T1, the association
between segmental T1 times and hypertrophy was non-
significant (p = 0.194; linear mixed effects model).
In family 2, the female H344P mutation carrier (17 years)
with asymmetric LVH and without LGE, had a mean mid-
myocardium T1 value of 966 ms.
T2-relaxation times were within normal limits in all
patients and there were no significant associations be-
tween hypertrophied segments and T2 time.
LGE
Of the six mutations carriers, only two had left ventricular
LGE, with 11 % and 22 % enhancement of total LV volume
(Fig. 2). These patients also had severe LV hypertrophy.
LGE was patchy and diffuse but focusing on the most
hypertrophic segments. None of the patients presented
LGE in the right ventricle.
Histology
The father in family 2 (H344P carrier), who did not
undergo CMR, had diffuse cardiac hypertrophy, LV and
RV wall thickness ad 31 and 9 mm, intracellular vacuoli-
zation with positive periodic acid-Schiff (PAS) staining
indicative of glycogen, and focal fibrosis in the explanted
heart. There was also increased amount of left and right
atrial fat.
Mutation negative sibling
The 19-year-old mutation negative sibling in family 1
had normal LV mass and wall thickness, normal RV free
wall thickness, but increased LV EDV (111 ml/m2 [2.8])
and decreased EF 55 % [−2.2].
Table 2 Ventricular volumes, function and masses of PRKAG2
mutation carriers compared to age, gender and body surface
area standardized reference values
All
(n = 6)
Value z-scorea
Left ventricle
End-diastolic volume, ml 163 (116–180)
End-diastolic volume index, ml/m2 90 (82–100) 0.6 (-0.1–1.6)
End-systolic volume, ml 63 (38–72)
End-systolic volume index, ml/m2 34 (28–42) 0.9 (-1.0–2.2)
Stroke volume, ml 99 (78–109)
Stroke volume index, ml/m2 57 (52–59) 0.3 (-0.3–1.0)
Cardiac output, l/min 5.9 (4.8–8.2)
Cardiac output index, l/(minam2) 3.5 (3.1–4.4)
LVEF, % 62 (58–67) −0.3 (-1.5–1.5)
Mass, g 137 (96–335)
Mass index, g/m2 78 (68–203) 2.1 (-0.1–18.8)
Right ventricle
End-diastolic volume, ml 167 (124–189)
End-diastolic volume index, ml/m2 95 (75–102) 0.3 (-1.0–0.9)
End-systolic volume, ml 68 (38–83)
End-systolic volume index, ml/m2 39 (23–45) 0.2 (-1.3–1.3)
Stroke volume, ml 99 (78–106)
Stroke volume index, ml/m2 56 (52–59) 0.2 (-0.2–0.7)
Cardiac output, l/min 5.8 (4.9–8.2)
Cardiac output index, l/(minam2) 3.5 (3.1–4.4)
RVEF, % 59 (56–69) 0.1 (-1.1–1.3)
Values are median (range)
Abbreviations: LVEF left ventricular ejection fraction, RVEF right ventricular
ejection fraction
aZ-scores were calculated using the normal reference values for adults by
Maceira A. et al. [30] and children by Buechel E. et al. [31]
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Discussion
We are the first to describe the comprehensive CMR
findings of six individuals with PRKAG2 mutation, known
to cause a unique defect of the cardiac cell metabolism
with intracellular deposition of glycogen. We found that
the distribution of LVH in PRKAG2 syndrome is eccen-
tric. Patients with markedly increased LV mass showed a
diffuse pattern of hypertrophy but predominantly in the
interventricular septum. On the other hand, four patients
with normal or only mildly increased LV mass exhibited a
non-symmetric mid-infero-lateral pattern of hypertrophy.
T1 values were lowest in patients with the R302Q muta-
tion, LVH and no LGE. Two patients with the PRKAG2
mutation and advanced disease showed intramyocardial,
patchy LGE in hypertrophic segments.
Hypertrophy
We found that in five patients with the R302Q mutation
(family 1), LVH demonstrated a similar diffuse pattern in
two patients with markedly increased LV mass, but a non-
symmetric mid-infero-lateral pattern in three patients
with normal LV masses. Also, one patient with the H344P
mutation (family 2) presented with non-symmetric mid-
infero-lateral pattern of LVH. Significant LVH in PRKAG2
patients have been demonstrated previously by echocardi-
ography [7, 34]. In the largest series of 45 PRKAG2 muta-
tion carriers, 78 % had LVH on echocardiography with a
mean LV wall thickness of 21 mm (range 13–45 mm), and
varying pattern of hypertrophy within families, 46 % having
concentric, 29 % asymmetric, and one distal hypertrophy,
with often eccentric distributions [4]. While concentric
hypertrophy seems to be more common in metabolic and
infiltrative cardiomyopathies [6], in sarcomeric HCM the
distribution of LVH is characteristically asymmetric and
heterogeneous, preferentially involving basal interventri-
cular septum and often extending into the lateral wall, the
posterior septum and LV apex [35].
Our finding of both diffuse and non-symmetric distribu-
tion of LVH in the same family may be explained by the
generally progressive nature of LVH in PRKAG2 car-
diomyopathy during follow-up [4], and the varying age of
disease onset. That is, PRKAG2 mutations may express in
Fig. 2 A 48-year-old male patient with PRKAG2 cardiac syndrome and a pacemaker. In short-axis and four chamber cine images septum is
severely hypertrophied (a-b) (black arrows). Maximal septal and lateral wall thickness was 31 mm and 25 mm, respectively. Papillary muscles were
excluded in the measurements. Anteroseptal, hypertrophic areas exhibit patchy late gadolinium enhancement (c-d) (white arrows). White arrow
heads indicate artefact from pacemaker lead
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the early stage with focal and mild LVH, which may
change to diffuse disease in the later stage. Another ex-
planation could be, that even in the same family and with
the same mutation, there would be varying patterns of
hypertrophy. Nevertheless, our study demonstrates that
CMR based accurate segmental analysis of wall thickness
revealed abnormal hypertrophy in all PRKAG2 mutation
carriers, even in those subjects with normal LV mass.
T1 and T2 mapping
Our study is the first one describing the behaviour of T1
or T2 times in a glycogen storage cardiomyopathy. In
family 1, three males with the R302Q mutation, LVH
but no LGE, presented with lower mean mid-myocardial
T1 values (918 ± 11 ms) compared to mutation negative
male sibling (963 ms) of their age and the mutation posi-
tive male with extensive hypertrophy and LGE (973 ms).
This is in accordance with the hypothesized T1 reduction
by intracellular glycogen in the absence of significant
fibrosis. Theoretically, intracellular glycogen as a macro-
molecule with hydrophilic bonding with water would
Fig. 3 A 16-year-old male patient with a PRKAG2 mutation. In short-axis cine image (a-b) inferolateral left ventricular wall is mildly hypertrophied
(10–11 mm, maximal z-score 2.3) (white arrow), no late gadolinium enhancement is present (c-d)
Table 3 Summary of ventricular wall thickness compared to
normal reference values and late gadolinium enhancement of
PRKAG2 mutation carriers
All
(n = 6)
Value z-scorea
Left ventricle
Left ventricular hypertrophyb 6 (100)
Maximal wall thickness, mm 13 (11–37) 3.2 (2.3–19.0)
LGE presence 2 (33)
LGE extent, % left ventricular volumec 17 (11–22)
Right ventricle
Free wall thickness, mm 5 (2–6)
LGE presence 0 (0)
Values are median (range) or n (%)
Abbreviation: LGE late gadolinium enhancement
aStandardized wall thickness (z-score), see Statistics section
bLeft ventricular hypertrophy was defined as > 2 z-score wall thickening in one
or more myocardial segments
cOnly two patients had LGE
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Fig. 4 (See legend on next page.)
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reduce T1-relaxation time, as shown in vitro [20, 21]. Pos-
sible lipid accumulation, demonstrated in a case report of
end-stage PRKAG2, might also potent T1 shortening [10].
On the other hand, in the advanced disease stage T1
values may be slightly increased as a result of pseudo-
normalization caused by extracellular fibrosis, as seen in
Anderson-Fabry disease [18, 19].
We were unable to verify the hypothesis of inverse as-
sociation between segmental T1 times and hypertrophy
in non-enhanced myocardium. After adjustment to fixed
effects caused by different segments on T1, the association
between T1 times and hypertrophy was non-significant.
This may be due to limited number of patients and the
fact that LVH was predominantly located in mid-infero-
lateral segments which also present lower T1 values in
normal myocardium [36].
In a previous study, it was estimated that normal na-
tive myocardial ShMOLLI T1 time is 962 ± 25 ms [29].
Piechnik et al. also showed that the principal biological
parameter influencing myocardial ShMOLLI T1 is the
female gender, T1 times of females under 45 years being
24 ms longer (blood 130 ms). In above 45-year-olds
ShMOLLI T1 values did not differ between the sexes.
The same study also reported no age-dependency of ei-
ther myocardial or blood T1 values in males. In our very
limited study population, the mean myocardial T1 value
Table 4 Mid-myocardium native T1 and T2 values of six study individuals (one R302Q mutation carrier lacked T1 and T2 mapping data)
Segment
Anterior Anteroseptal Inferoseptal Inferior Inferolateral Anterolateral Mean
Native T1 values
Family 1 (n = 5)
R302Q mutation (n = 4)
LGE negative (n = 3)
1 934 932 944 905 897 929 924
2 914 902 925 924 879 894 906
3 922 938 945 919 905 918 925
Mean 923 924 938 916 894 914 918
LGE positive (n = 1) m. v. m. v. 990 944 986 m. v. 973
No mutation (n = 1) 984 954 938 960 984 955 963
Family 2 (n = 1)
H344P mutation (n = 1) 950 965 985 968 957 969 966
Native T2 values
Family 1 (n = 5)
R302Q mutation (n = 4)
LGE negative (n = 3)
1 42.8 44.4 39.9 39.7 43.9 40.5 41.9
2 41.4 44.3 43.8 43.0 43.2 40.3 42.7
3 42.1 46.5 42.2 40.5 45.5 40.2 42.8
Mean 42.1 45.1 42.0 41.1 44.2 40.3 42.5
LGE positive (n = 1) m. v. m. v. 41.9 40.2 39.9 m. v. 40.7
No mutation (n = 1) 43.3 47.6 41.5 37.2 43.2 39.0 42.0
Family 2 (n = 1)
H344P mutation (n = 1) 50.4 50.0 49.0 45.4 50.4 45.4 48.4
M.V. missing value (artefact by pacemaker)
Abbreviation: LGE late gadolinium enhancement
(See figure on previous page.)
Fig. 4 Distribution of left ventricular hypertrophy of six PRKAG2 mutation carriers. Upper and lower values represent absolute (mm) and
standardized (z-score) maximal wall thickness in the segment using adult references. Gray scaling of each segment is based on z-score. Members
of family 1 with an R302Q mutation: I:1 (a), II:1 (b), II:2 (c), II:3 (d) and II:4 (e). A member of family 2 with an H344P-mutation: II:1 (f). The 16-year-old male
(e), with body-surface-area (BSA) of 1.33 m2, had hypertrophy in mid-infero-lateral segment (posterior free wall) of 10 mm (z-score 2.3) using the
BSA-standardized echocardiography based reference values for children
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of the 17-year-old female H344P mutation carrier was
966 ms, whereas T1 values of male R302Q mutation car-
riers were from 906 to 973 ms; thus the differences
caused by gender and mutation type may attenuate the
possible changes related to intracellular glycogen.
All our patients had normal T2-relaxation times. Nor-
mal T2 times exclude possible iron accumulation in the
myocardium and its effect on T1 values [37, 38].
Late gadolinium enhancement
In this study, patients with significant LVH and in-
creased LV mass, had widespread LGE. In an earlier case
report of a patient with large cardiomyocyte vacuoles
due to extensive cytosolic accumulation of glycogen in
Danon disease (a mutation of the LAMP2 gene), CMR
demonstrated both RV and LV dysfunction, and extensive
homogeneous LGE of the RV with concomitant patchy
midwall LV involvement [39]. This was suggested to be
caused by sarcolemmal damage in an advanced storage
disease and subsequent gadolinium retention within intra-
cellular space [39]. Similar mechanism of LGE has been
suggested in Anderson-Fabry disease, with intracellular
lipid accumulation [18], and could also explain LGE in
our patients with the progressive stage of PRKAG2.
Study limitations
The reference values used for calculating z-scores of LV
wall thickness according to AHA 17-segment model
were based on the largest available study on participants
free of cardiac disease (similar software tool, MR scanner
and sequence) with a mean age of 66 ± 9 years, which is
considerably higher than our patients (median age
23 years, range 16–48). Therefore, we presented both
absolute and standardized values of wall thickness when
appropriate. In 16 myocardial segments, there is consid-
erable probability to achieve abnormal z-scores in some
segments by change. To overcome this, we plotted the
distribution of z-scores in each patient to study the con-
sistency of values in adjacent segments.
Our cohort was too small to find correlations between
age, symptom duration and disease severity. We did not
study the time-related changes in the myocardium. How-
ever, according to an earlier study, cardiac hypertrophy
has a generally progressive nature in PRKAG2 [4], and
thus different patterns of LVH in the same family may
represent different stages of the disease. This study also
lacks histological validation of imaging findings, although
we presented the histology of the explanted heart of the
father in family 2.
Conclusions
PRKAG2 cardiac syndrome may present with eccentric
distribution of LVH, involving focal mid-infero-lateral pat-
tern in the early disease stage, and more diffuse pattern
but focusing on interventricular septum in advanced cases.
In patients at earlier stages of the disease, without LGE, T1
values may be reduced, while in the advanced disease stage
T1 mapping may result in higher values caused by fibrosis.
CMR is a valuable tool in detecting diffuse and focal myo-
cardial abnormalities in PRKAG2 cardiomyopathy.
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